MAPT and early-onset autosomal dominant Alzheimer disease: Results from nonclinical and clinical studies so far have shown that florzolotau binds to tau lesions with high affinity and less non-specific off-target binding including MAO-B and MAO-A, and shown the probe captures not only Alzheimer’s disease but also non-Alzheimer-type tau pathologies with a dynamic range sufficient for differentiation [13, 14], and these findings have been confirmed by other investigators [15].